Sharon Simon 4

What Happened

• Sharon Simon, General Manager and Chief Technology Officer of Microbot Medical Inc., received a grant of derivative securities covering 105,000 shares on February 18, 2026. The Form 4 reports the acquisition as a derivative award (transaction code A) with no cash paid at grant ($0.00 reported). Per the filing footnote, these are options that will become exercisable according to the issuer’s 2020 Omnibus Performance Award Plan.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (timely filing).
• Amount: 105,000 derivative shares (option award); cash paid at grant: $0.00 (no immediate purchase).
• Vesting (from footnote): 25% vests and becomes exercisable on August 18, 2026; the remaining 75% vests equally on a quarterly basis over the subsequent 30 months, subject to acceleration or forfeiture under the Plan.
• Shares owned after the transaction: not disclosed in the filing.
• This is an award/option grant (compensation/retention), not an open‑market purchase or sale.

Context

• These are time‑vesting options (per the footnote) and are not immediately exercisable in full; they do not represent an immediate sale or open‑market purchase. The filing does not state an exercise price or immediate cash consideration—terms are governed by the company’s 2020 Omnibus Performance Award Plan.